ReviewCancers2026

Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology.

Satoshi Ikeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.